Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $51.2 million.

  • Ani Pharmaceuticals' Accumulated Expenses rose 7210.26% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year increase of 7210.26%. This contributed to the annual value of $37.7 million for FY2024, which is 5860.17% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Accumulated Expenses is $51.2 million, which was up 7210.26% from $36.0 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Accumulated Expenses peaked at $51.2 million during Q3 2025, and registered a low of $4.9 million during Q3 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $13.1 million (2023), whereas its average is $18.2 million.
  • In the last 5 years, Ani Pharmaceuticals' Accumulated Expenses tumbled by 1962.88% in 2021 and then soared by 13066.33% in 2023.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Accumulated Expenses stood at $8.5 million in 2021, then increased by 21.0% to $10.3 million in 2022, then skyrocketed by 130.66% to $23.8 million in 2023, then surged by 58.6% to $37.7 million in 2024, then surged by 35.84% to $51.2 million in 2025.
  • Its Accumulated Expenses stands at $51.2 million for Q3 2025, versus $36.0 million for Q2 2025 and $23.7 million for Q1 2025.